Pet Pharm Biotech Co (ROCO:7762) Total Receivables: NT$59.4 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
19 GF Score
Price NT$49.85
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co Total Receivables?

Pet Pharm Biotech Co ROCO:7762 +0.20% 19 Total Receivables is NT$59.4 Mil as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Pet Pharm Biotech Co's Total Receivables for the quarter that ended in Dec. 2025 was NT$59.4 Mil.

Pet Pharm Biotech Co Total Receivables Related Terms

Pet Pharm Biotech Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Total Receivables Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Receivables
20.91 31.24 33.78 59.35

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial 31.24 32.56 33.78 41.59 59.35
ROCO:7762
19GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of NT$59.4 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a Total Receivables of NT$59.4 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Pet Pharm Biotech Co and its competitors.
Is Pet Pharm Biotech Co's Total Receivables too high?
Pet Pharm Biotech Co's current Total Receivables is NT$59.4 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Total Receivables compare to LLY and JNJ?
Pet Pharm Biotech Co's Total Receivables of NT$59.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Total Receivables is NT$59.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Total Receivables of NT$59.4 Mil. The current Total Receivables is NT$59.4 Mil. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Total Receivables is NT$59.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score

Get the complete analysis for ROCO:7762

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.85
Price